NCT07200206View on ClinicalTrials.gov

A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

Not yet recruitingOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 29, 2030

Study Completion Date

April 29, 2030

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL

Nirsevimab

Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT07200206 - A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea | Biotech Hunter | Biotech Hunter